Premium
Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: Intermediate‐term risk of recurrent neurological events
Author(s) -
Du ZhongDong,
Cao QiLing,
Joseph Annette,
Koenig Peter,
Heischmidt Mary,
Waight David J.,
Rhodes Jonathan,
Brorson James,
Hijazi Ziyad M.
Publication year - 2002
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10067
Subject(s) - medicine , patent foramen ovale , paradoxical embolism , surgery , fluoroscopy , embolism , catheter , closure (psychology) , foramen ovale (heart) , cardiology , percutaneous , economics , market economy
Closure of patent foramen ovale (PFO) has been proposed as an alternative to anticoagulation in patients with presumed paradoxical emboli. We report our preliminary intermediate results of patients who underwent transcatheter PFO closure for paradoxical embolism using DAS‐Angel Wings occluder or Amplatzer devices. Eighteen patients (8 male/10 female) underwent catheter closure of their PFOs at a median age of 42 years. The complete closure rate was 67% immediately after the procedure and 100% at a mean follow‐up interval of 2.2 ± 1.8 years. The mean fluoroscopy time and procedure time in the Amplatzer group were 8.5 ± 3.2 min and 65 ± 21 min, respectively, which were significantly shorter than those of DAS‐Angel Wings group (18.9 ± 4.7 min and 137 ± 28 min, respectively). There were no recurrent embolic neurological events following device placement in this subset of patients. No complications were encountered either during or after the closure procedure. In conclusion, transcatheter closure of PFO seems to be an effective alternative therapy in the prevention of presumed paradoxical emboli. Further study is needed to identify patients most likely to benefit from this intervention. Cathet Cardiovasc Intervent 2002;55:189–194. © 2002 Wiley‐Liss, Inc.